ER-176
Semantic Dementia
Mayo ClinicSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Semantic Dementia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Namenda University of California, San Francisco | Phase 4 | BB |
FLUDEOXYGLUCOSE Mayo Clinic | Phase 1 | CC |
PITTSBURGH COMPOUND B UNLABELLED Mayo Clinic | Phase 1 | CC |
Verdiperstat Peter Ljubenkov, MD | Phase 1 | CC |
FLORTAUCIPIR Mayo Clinic | D |
Same molecule, other indications
ER-176 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →